Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year

Timucin Taner, M. J. Gandhi, S. O. Sanderson, C. R. Poterucha, S. R. De Goey, Mark D Stegall, J. K. Heimbach

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

The presence of preformed donor-specific HLA antibodies (DSA) in liver transplant recipients is increasingly recognized; however, the prevalence of DSA and their impact on early allograft function remains unknown. We prospectively followed serum DSA levels of 90 consecutive liver transplant recipients from baseline to 4 months. Twenty recipients (22.2%) had preformed DSA. No antibody-targeting treatments were undertaken. Seven days after transplantation, DSA levels decreased markedly in all but three patients. Day 7 protocol biopsies showed diffuse C4d deposition along the portal stroma, central vein, subendothelial and stromal space in the patients with persistent high DSA levels. The rate of acute cellular rejection was not significantly different in patients with DSA. The transaminase and bilirubin levels remained comparable during the first year despite the presence of DSA. The three patients with persistently high DSA levels continue to have normal allograft function. We conclude that in most cases, DSA disappear after liver transplant, however in rare instances where they persist, there is evidence of complement activation in the liver allograft, without significant clinical impact in the first year. Preformed donor-specific antibodies rarely persist after liver transplant and have no significant clinical impact in the first year.

Original languageEnglish (US)
Pages (from-to)1504-1510
Number of pages7
JournalAmerican Journal of Transplantation
Volume12
Issue number6
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Liver Transplantation
Tissue Donors
Antibodies
Liver
Allografts
Transplants
Complement Activation
Transaminases
Bilirubin
Veins
Transplantation
Biopsy

Keywords

  • Complement C4d
  • donor-specific antibodies
  • HLA antibodies
  • liver transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. / Taner, Timucin; Gandhi, M. J.; Sanderson, S. O.; Poterucha, C. R.; De Goey, S. R.; Stegall, Mark D; Heimbach, J. K.

In: American Journal of Transplantation, Vol. 12, No. 6, 06.2012, p. 1504-1510.

Research output: Contribution to journalArticle

Taner, Timucin ; Gandhi, M. J. ; Sanderson, S. O. ; Poterucha, C. R. ; De Goey, S. R. ; Stegall, Mark D ; Heimbach, J. K. / Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. In: American Journal of Transplantation. 2012 ; Vol. 12, No. 6. pp. 1504-1510.
@article{c2e18252c01143669b9f66edbff1f9f8,
title = "Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year",
abstract = "The presence of preformed donor-specific HLA antibodies (DSA) in liver transplant recipients is increasingly recognized; however, the prevalence of DSA and their impact on early allograft function remains unknown. We prospectively followed serum DSA levels of 90 consecutive liver transplant recipients from baseline to 4 months. Twenty recipients (22.2{\%}) had preformed DSA. No antibody-targeting treatments were undertaken. Seven days after transplantation, DSA levels decreased markedly in all but three patients. Day 7 protocol biopsies showed diffuse C4d deposition along the portal stroma, central vein, subendothelial and stromal space in the patients with persistent high DSA levels. The rate of acute cellular rejection was not significantly different in patients with DSA. The transaminase and bilirubin levels remained comparable during the first year despite the presence of DSA. The three patients with persistently high DSA levels continue to have normal allograft function. We conclude that in most cases, DSA disappear after liver transplant, however in rare instances where they persist, there is evidence of complement activation in the liver allograft, without significant clinical impact in the first year. Preformed donor-specific antibodies rarely persist after liver transplant and have no significant clinical impact in the first year.",
keywords = "Complement C4d, donor-specific antibodies, HLA antibodies, liver transplantation",
author = "Timucin Taner and Gandhi, {M. J.} and Sanderson, {S. O.} and Poterucha, {C. R.} and {De Goey}, {S. R.} and Stegall, {Mark D} and Heimbach, {J. K.}",
year = "2012",
month = "6",
doi = "10.1111/j.1600-6143.2012.03995.x",
language = "English (US)",
volume = "12",
pages = "1504--1510",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year

AU - Taner, Timucin

AU - Gandhi, M. J.

AU - Sanderson, S. O.

AU - Poterucha, C. R.

AU - De Goey, S. R.

AU - Stegall, Mark D

AU - Heimbach, J. K.

PY - 2012/6

Y1 - 2012/6

N2 - The presence of preformed donor-specific HLA antibodies (DSA) in liver transplant recipients is increasingly recognized; however, the prevalence of DSA and their impact on early allograft function remains unknown. We prospectively followed serum DSA levels of 90 consecutive liver transplant recipients from baseline to 4 months. Twenty recipients (22.2%) had preformed DSA. No antibody-targeting treatments were undertaken. Seven days after transplantation, DSA levels decreased markedly in all but three patients. Day 7 protocol biopsies showed diffuse C4d deposition along the portal stroma, central vein, subendothelial and stromal space in the patients with persistent high DSA levels. The rate of acute cellular rejection was not significantly different in patients with DSA. The transaminase and bilirubin levels remained comparable during the first year despite the presence of DSA. The three patients with persistently high DSA levels continue to have normal allograft function. We conclude that in most cases, DSA disappear after liver transplant, however in rare instances where they persist, there is evidence of complement activation in the liver allograft, without significant clinical impact in the first year. Preformed donor-specific antibodies rarely persist after liver transplant and have no significant clinical impact in the first year.

AB - The presence of preformed donor-specific HLA antibodies (DSA) in liver transplant recipients is increasingly recognized; however, the prevalence of DSA and their impact on early allograft function remains unknown. We prospectively followed serum DSA levels of 90 consecutive liver transplant recipients from baseline to 4 months. Twenty recipients (22.2%) had preformed DSA. No antibody-targeting treatments were undertaken. Seven days after transplantation, DSA levels decreased markedly in all but three patients. Day 7 protocol biopsies showed diffuse C4d deposition along the portal stroma, central vein, subendothelial and stromal space in the patients with persistent high DSA levels. The rate of acute cellular rejection was not significantly different in patients with DSA. The transaminase and bilirubin levels remained comparable during the first year despite the presence of DSA. The three patients with persistently high DSA levels continue to have normal allograft function. We conclude that in most cases, DSA disappear after liver transplant, however in rare instances where they persist, there is evidence of complement activation in the liver allograft, without significant clinical impact in the first year. Preformed donor-specific antibodies rarely persist after liver transplant and have no significant clinical impact in the first year.

KW - Complement C4d

KW - donor-specific antibodies

KW - HLA antibodies

KW - liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=84861800894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861800894&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2012.03995.x

DO - 10.1111/j.1600-6143.2012.03995.x

M3 - Article

C2 - 22420671

AN - SCOPUS:84861800894

VL - 12

SP - 1504

EP - 1510

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 6

ER -